Clinical efficacy of hypofractionated radiotherapy for patients with locally advanced or advanced non-small cell lung cancer
10.3760/cma.j.cn113030-20200728-00383
- VernacularTitle:大分割放疗在局部晚期或晚期非小细胞肺癌中的疗效
- Author:
Jiajia ZHANG
1
;
Yipeng CAO
;
Siying CHEN
;
Jun WANG
;
Lujun ZHAO
;
Ping WANG
;
Ningbo LIU
Author Information
1. 天津医科大学肿瘤医院放疗科 国家肿瘤临床医学研究中心 天津市"肿瘤防治"重点实验室 天津市恶性肿瘤临床医学研究中心 300060
- Keywords:
Lung neoplasm/hypofractionated radiotherapy;
Treatment outcome;
Safety
- From:
Chinese Journal of Radiation Oncology
2021;30(10):1002-1006
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the survival outcome and toxicity of hypofractionated radiotherapy (45 Gy/15f) in patients with locally advanced/advanced non-small cell lung cancer (NSCLC) who are ineligible for conventional fractionated radiotherapy.Methods:The early efficacy, survival and toxicity of inoperable patients ( n=64) with locally advanced/advanced NSCLC patients admitted to Cancer Hospital of Tianjin Medical University from 2014 to 2018 were retrospectively analyzed. Hypofractionated radiotherapy (45 Gy/15f) were performed by using intensity-modulated radiotherapy or volumetric-modulated arc therapy technologies on Pinnacle 9 planning system. Results:The median follow-up time was 26 months. The early efficacy was available in 58 patients: complete response for 2 cases (3%), partial response for 22(38%), stable disease for 28(44%) and progressive disease for 6(9%), respectively. The local control rate was 90%. The median time to progression (TTP) and the median overall survival (OS) for all patients was 8.2 months and 21.0 months, respectively. The 1-, 2-and 3-year TTP rate was 37%, 28%, 14% and the OS rate was 66%, 43% and 27%, respectively. The incidence of esophagitis was 17%( n=11), 19%( n=12) for radiation pneumonitis and 20%( n=13) for myelosuppression. No grade ≥3 esophagitis or pneumonia was found. Conclusion:Hypofractionated radiotherapy (45 Gy/15f) is efficacious and safe for patients with locally advanced/advanced NSCLC, which yields controllable adverse events.
